Our top pick for
Building a portfolio
PDL BioPharma, Inc is a biotechnology business based in the US. PDL BioPharma shares (PDLI) are listed on the NASDAQ and all prices are listed in US Dollars. PDL BioPharma employs 109 staff and has a trailing 12-month revenue of around USD$27.8 million.
|Latest market close||USD$2.45|
|52-week range||USD$2.09 - USD$3.86|
|50-day moving average||USD$2.3129|
|200-day moving average||USD$2.9427|
|Wall St. target price||USD$2.5|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$0.006|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-13)||N/A|
|1 month (2020-12-24)||-8.58%|
|3 months (2020-10-20)||N/A|
|6 months (2020-07-20)||N/A|
|1 year (2020-01-20)||N/A|
|2 years (2019-01-20)||N/A|
|3 years (2018-01-20)||N/A|
|5 years (2016-01-20)||N/A|
Valuing PDL BioPharma stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of PDL BioPharma's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
PDL BioPharma's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 477x. In other words, PDL BioPharma shares trade at around 477x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
PDL BioPharma's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.4. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into PDL BioPharma's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
|Revenue TTM||USD$27.8 million|
|Gross profit TTM||USD$13.4 million|
|Return on assets TTM||-4.1%|
|Return on equity TTM||-7.36%|
|Market capitalisation||USD$295.8 million|
TTM: trailing 12 months
There are currently 10.6 million PDL BioPharma shares held short by investors – that's known as PDL BioPharma's "short interest". This figure is 4% down from 11.0 million last month.
There are a few different ways that this level of interest in shorting PDL BioPharma shares can be evaluated.
PDL BioPharma's "short interest ratio" (SIR) is the quantity of PDL BioPharma shares currently shorted divided by the average quantity of PDL BioPharma shares traded daily (recently around 1.0 million). PDL BioPharma's SIR currently stands at 10.4. In other words for every 100,000 PDL BioPharma shares traded daily on the market, roughly 10400 shares are currently held short.
However PDL BioPharma's short interest can also be evaluated against the total number of PDL BioPharma shares, or, against the total number of tradable PDL BioPharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case PDL BioPharma's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 PDL BioPharma shares in existence, roughly 90 shares are currently held short) or 0.0959% of the tradable shares (for every 100,000 tradable PDL BioPharma shares, roughly 96 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against PDL BioPharma.
Find out more about how you can short PDL BioPharma stock.
We're not expecting PDL BioPharma to pay a dividend over the next 12 months.
PDL BioPharma's shares were split on a 2:1 basis on 10 October 2001. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your PDL BioPharma shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for PDL BioPharma shares which in turn could have impacted PDL BioPharma's share price.
Over the last 12 months, PDL BioPharma's shares have ranged in value from as little as $2.09 up to $3.86. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while PDL BioPharma's is 1.08. This would suggest that PDL BioPharma's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
PDL BioPharma, Inc. manages various patents in the United States and internationally. The company's patents cover humanization of antibodies. It also offers notes and other long-term receivables services, as well as engages in the equity investment activities. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.
Steps to owning and managing SSNC, with 24-hour and historical pricing before you buy.
Steps to owning and managing SMBC, with 24-hour and historical pricing before you buy.
Steps to owning and managing SMED, with 24-hour and historical pricing before you buy.
Steps to owning and managing SJW, with 24-hour and historical pricing before you buy.
Steps to owning and managing SFBS, with 24-hour and historical pricing before you buy.
Steps to owning and managing LEDS, with 24-hour and historical pricing before you buy.
Steps to owning and managing SC, with 24-hour and historical pricing before you buy.
Steps to owning and managing RTW, with 24-hour and historical pricing before you buy.
Steps to owning and managing RIVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing RVSB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.